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The dyslipidemia associated with chronic kidney disease
(CKD) is characterized by elevated levels of triglycerides
(TG) and lower concentrations of high-density lipoprotein
cholesterol (HDL). Treatment options include an array of
therapies, all of which have benefit-to-risk relationships that
deserve careful consideration. Fibrates or fibric acid deriva-
tives induce lipoprotein lipolysis by acting as ligands to the
peroxisome proliferator–activated receptor alpha () sub-
nit, activating the transcription of multiple genes including
hose that up-regulate lipoprotein lipase, a catabolic enzyme
1). Increased lipoprotein lipase enhances the metabolism of
G-rich particles, including chylomicrons and very low-density
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lipoprotein (VLDL) (2,3). In addition, peroxisome proliferator–
activated receptor stimulation influences multiple pathways in
reverse cholesterol transport (1). Triglycerides are also a
substantial component of intermediate-density lipoprotein
(IDL), and comprise 50% of low-density lipoprotein
(LDL) particles. Fibric acid derivatives reduce fasting
TG values by 15% to 50% (depending on baseline
level— greater reductions with higher levels), LDL by
8%, and raise HDL by 9% (4). In conjunction with a
statin, the amount of TG lowering is approximately
doubled with the addition of the fibrate. Fibrates decrease
the TG concentration of LDL particles while increasing
the TG content of LDL particles (5). Thus, the mean size
of LDL particles increases, with a substantial reduction in
the number and proportion of small dense LDL particles
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Both authors have reported they have no relationships relevant to the contents of this
paper to disclose.(4,6). When there is fasting hypertriglyceridemia (TG
200 mg/dl) and the TG concentration is sufficiently
lowered by a fibrate, large randomized trials have shown
relative risk reductions of 27% to 65% in cardiovascular
(CV) endpoints including nonfatal myocardial infarction
and CV death (4). Conversely, when TG concentrations are
normal (150 mg/dl), further reductions do not measur-
ably influence LDL particle size or number and as a
result, there is no CV benefit. Thus, fibrates are a
second-line preventive therapy after statins in patients
with residual elevations in non-HDL cholesterol and
hypertriglyceridemia in the general population, however,
their role in patients with CKD has yet to be defined
given their unique effects in this subgroup (7).
Reduced renal blood flow and glomerular filtration have
been a consistent secondary effect seen with fibric acid
derivatives (8). Reductions are mild and reverse within 2
weeks of drug discontinuation (9). It has been postulated
that this effect is due to a reduction in the production of
vasodilatory renal prostaglandins (10). In this issue of the
Journal, Jun et al. (11) report the results of a meta-analysis
of fibrates in the subgroup of patients with baseline CKD.
While the authors did not report the baseline TG concen-
tration of the CKD subgroups in these trials, it is expected
that the CKD patients would have had a higher TG
concentration than the general population due to impaired
plasma clearance of VLDL, and thus, could realize a CV
benefit from the 50% TG reduction observed (12). In-
deed, in the CKD subgroup, fibrates were associated with a
30% reduction in nonfatal CV events and a 40% reduction
in CV death, both of which were statistically significant. At
the same time, there was a 14% reduction in the progression
of microalbuminuria but an elevation of serum creatinine of
25%. There was no significant difference in the incidence
of end-stage renal disease. Thus, the reduction in renal
filtration appeared to lessen albuminuria and elevate serum
creatinine but did not impact the progression of CKD to
renal replacement therapy.
This report provides further support and clarity on the
cardiovascular benefit of fibrates in those with baseline
elevated TG and non–HDL-cholesterol. Furthermore,
there appears to be a cardiorenal benefit of this class of
drugs in reducing renal blood flow and to an extent,
attenuating glomerular hyperfiltration and microalbu-
minuria. In general, fibrates are some of the best tolerated
drugs to treat dyslipidemia and the paper by Jun and
coworkers supports their use in patients with CKD (7).
Clinicians should recognize that using drugs which
antagonize the renin-angiotensin system, thereby reduc-
ing glomerular filtration, can be protective against the
progression of CKD. Future trials should plan a priori
cardiorenal endpoints for lipid lowering therapy when
off-target pharmacologic effects are possible. In some
cases such as fibrates, there can be dual benefits.
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